Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 14/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | MMEL1 | Q495T6 | 2/20 | 0.38 |
| ▸ | MME | P08473 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17227455 | 0.89 | DPP4 (0.44) | DPP4 | |
| SCHEMBL699084 | 0.88 | DPP4 (0.39) | DPP4PIN1MMEL1MME | |
| SCHEMBL699083 | 0.88 | DPP4 (0.39) | DPP4PIN1MMEL1MME | |
| SCHEMBL28759095 | 0.87 | DPP4 (0.43) | DPP4PIN1 | |
| SCHEMBL29364846 | 0.87 | DPP4 (0.43) | DPP4PIN1 | |
| SCHEMBL342707 | 0.87 | DPP4 (0.43) | DPP4PIN1 | |
| SCHEMBL342708 | 0.87 | DPP4 (0.43) | DPP4PIN1 | |
| SCHEMBL463397 | 0.85 | DPP4 (0.38) | DPP4PIN1MMEL1MMECYP3A4 | |
| SCHEMBL25075296 | 0.85 | DPP4 (0.40) | DPP4PIN1MMEL1MMECYP3A4 | |
| SCHEMBL15103376 | 0.85 | DPP4 (0.40) | DPP4PIN1MMEL1MMECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524936-B2 | Manufacturing process for sitagliptin from L-aspartic acid | SOUKUP MILAN (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524936-B2 | Manufacturing process for sitagliptin from L-aspartic acid | SOUKUP MILAN (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524936-B2 | Manufacturing process for sitagliptin from L-aspartic acid | SOUKUP MILAN (US) | 2013-09-03 | — | — | US | disclosed |
| WO-2012156888-A1 | MANUFACTURING PROCESS FOR SITAGLIPTIN FROM L-ASPARTIC ACID | DRUG PROCESS LICENSING ASS., LLC (US) | 2012-11-22 | — | — | WO | disclosed |
| US-20120123144-A1 | Manufacturing process for sitagliptin from L-aspartic acid | Drug Process Licensing Associates, LLC (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123144-A1 | Manufacturing process for sitagliptin from L-aspartic acid | DPP4, DPP9, DPP7 | DPP4 1/4885PIN1 2077/4885MMEL1 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.